The stock has responded positively to the sustained operational excellence, trading at ₹556.40 as of February 13, 2026, though it has retraced 11.32% from its 52-week high of ₹627.45. Despite near-term volatility, the company's consistent margin expansion and strong volume growth underscore improving competitive positioning in the global generics market.
The December 2025 quarter represents the culmination of a strong nine-month performance for Granules India, with the company posting cumulative revenues of ₹3,895.02 crores for the first three quarters of FY26, up 18.93% from the corresponding period last year. Net profit for the nine-month period stood at ₹393.46 crores, reflecting a growth of 13.84% YoY, demonstrating consistent execution across business verticals.
| Metric (₹ Cr) | Dec'25 | Sep'25 | Jun'25 | Mar'25 | Dec'24 | Sep'24 | Jun'24 |
|---|---|---|---|---|---|---|---|
| Net Sales | 1,387.94 | 1,296.98 | 1,210.10 | 1,197.43 | 1,137.70 | 966.62 | 1,179.86 |
| QoQ Growth | +7.01% | +7.18% | +1.06% | +5.25% | +17.70% | -18.07% | — |
| YoY Growth | +22.00% | +34.18% | +2.56% | — | — | — | — |
| Operating Profit | 308.10 | 278.22 | 246.71 | 252.36 | 230.30 | 203.32 | 259.26 |
| Operating Margin | 22.36% | 21.49% | 20.41% | 21.09% | 20.32% | 21.26% | 22.18% |
| Net Profit | 150.21 | 130.61 | 112.64 | 152.03 | 117.60 | 97.23 | 134.65 |
| QoQ Growth | +15.01% | +15.95% | -25.91% | +29.28% | +20.95% | -27.79% | — |
| YoY Growth | +27.73% | +34.33% | -16.35% | — | — | — | — |
| PAT Margin | 10.90% | 10.09% | 9.32% | 12.70% | 10.37% | 10.16% | 11.52% |
Financial Performance: Margin Expansion Drives Bottom-Line Growth
Granules India's Q3 FY26 results showcase impressive financial discipline and operational efficiency. Net sales of ₹1,387.94 crores represent a sequential growth of 7.01% over Q2 FY26 and a robust 22.00% expansion compared to the corresponding quarter last year. This marks the seventh consecutive quarter of sequential revenue growth, demonstrating strong demand across the company's pharmaceutical portfolio.
The standout feature of the quarter was the significant margin expansion across all profitability metrics. Operating profit (PBDIT excluding other income) surged to ₹308.10 crores, yielding an operating margin of 22.36%, the highest in the trailing seven quarters. This represents a 204 basis points improvement over December 2024's margin of 20.32%, reflecting better product mix, improved capacity utilisation, and effective cost management initiatives.
Net profit advanced 15.01% sequentially and 27.73% year-on-year to ₹150.21 crores, translating to a PAT margin of 10.90%. The margin improvement of 53 basis points YoY and 81 basis points QoQ underscores the company's ability to convert top-line growth into meaningful bottom-line expansion. Notably, the absolute profit figure represents the highest quarterly PAT in company history, surpassing the previous peak of ₹152.03 crores recorded in March 2025.
Employee costs rose to ₹225.96 crores in Q3 FY26, up 34.79% YoY, reflecting strategic investments in talent acquisition and retention as the company scales operations. Interest expenses remained relatively stable at ₹28.69 crores, whilst depreciation increased to ₹73.53 crores, in line with ongoing capital expenditure programmes to expand manufacturing capacity. The tax rate for the quarter stood at 25.72%, slightly higher than the previous year's 23.03%, though remaining within the company's guided range.
Earnings Quality: Strong Operational Performance
The quality of earnings remains robust, with operating profit to interest coverage reaching 10.74 times in Q3 FY26, the highest in the trailing period. Cash and cash equivalents for the half-year period stood at ₹619.01 crores, providing substantial financial flexibility. The debtors turnover ratio improved to 6.36 times for H1 FY26, indicating efficient working capital management and strong cash conversion cycles.
Operational Excellence: Capacity Utilisation and Product Mix Drive Performance
Granules India's operational metrics reflect the company's strengthening competitive position in the global pharmaceutical landscape. The company's vertically integrated business model—spanning APIs, pharmaceutical formulation intermediates (PFIs), and finished dosages—provides significant strategic advantages in terms of cost control, quality assurance, and supply chain resilience.
Return on equity (ROE) stands at 15.81% on an average basis, demonstrating efficient capital deployment and strong shareholder value creation. This positions Granules India favourably within its peer group, reflecting management's ability to generate superior returns on invested capital. The company's return on capital employed (ROCE) of 18.24% on an average basis further underscores operational efficiency, though the latest half-yearly ROCE of 13.29% suggests some near-term pressure from capacity expansion investments.
The company's balance sheet remains healthy with a net debt to equity ratio of 0.30, indicating conservative leverage levels. Long-term debt stood at ₹311.51 crores as of March 2025, whilst the debt to EBITDA ratio of 1.41 times reflects comfortable debt servicing capacity. Fixed assets increased to ₹2,231.10 crores, reflecting ongoing capital investments in manufacturing infrastructure to support future growth.
Working capital management has improved notably, with current assets of ₹3,115.48 crores comfortably exceeding current liabilities of ₹2,003.16 crores as of March 2025. The company generated operating cash flow of ₹866.00 crores in FY25, more than doubling from ₹439.00 crores in FY24, demonstrating strong cash generation capabilities despite increased working capital requirements.
Monitoring Point: Interest Cost Trajectory
Whilst overall financial performance remains strong, interest costs for the latest six-month period stood at ₹57.88 crores, representing growth of 21.19% over the corresponding period. This increase, though manageable given the company's strong EBIT to interest coverage of 12.20 times on average, warrants monitoring as the company continues its capacity expansion programme. The company's ability to maintain strong interest coverage ratios will be crucial as it scales operations.
Industry Context: Positioning in the Global Generics Market
The global pharmaceutical industry continues to present significant opportunities for vertically integrated manufacturers like Granules India. The company's focus on "first line of defence" products such as paracetamol, ibuprofen, metformin, and guaifenesin positions it well in the off-patent drugs segment, which benefits from stable demand patterns and relatively insulated competitive dynamics.
The pharmaceutical sector in India has demonstrated resilience, with the broader pharmaceuticals and biotechnology industry posting a one-year return of 4.78%. Granules India's one-year return of 2.85% represents a modest underperformance of 1.93 percentage points versus the sector, though this gap has narrowed considerably over longer time horizons. The company's three-year return of 94.75% significantly outpaces the sector average, reflecting the successful execution of its strategic initiatives over the medium term.
Granules India's competitive advantages stem from its integrated manufacturing capabilities, which allow for better cost control and quality assurance compared to pure-play finished dosage manufacturers. The company's scale in key APIs provides pricing power and supply security for its downstream formulation business. Additionally, regulatory approvals and established customer relationships in developed markets create meaningful barriers to entry for competitors.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity | Div Yield (%) |
|---|---|---|---|---|---|
| Granules India | 24.91 | 3.39 | 15.81 | 0.30 | 0.27 |
| Acutaas Chemical | 57.52 | 11.68 | 12.59 | -0.16 | 0.07 |
| Neuland Labs | 93.42 | 10.33 | 14.60 | 0.06 | 0.09 |
| Alembic Pharma | 22.67 | 2.83 | 11.80 | 0.25 | 1.44 |
| Natco Pharma | 9.42 | 1.70 | 16.25 | -0.34 | 0.61 |
| Jubilant Pharmo | 31.42 | 2.20 | 6.76 | 0.34 | 0.55 |
Peer Comparison: Competitive Positioning and Valuation
Granules India occupies a distinctive position within the pharmaceutical peer group, balancing strong operational metrics with reasonable valuation multiples. The company's ROE of 15.81% ranks second amongst the peer set, trailing only Natco Pharma's 16.25% but significantly ahead of Jubilant Pharmo's 6.76% and Alembic Pharma's 11.80%. This superior return profile reflects the company's operational efficiency and effective capital allocation strategies.
From a valuation perspective, Granules India trades at a price-to-earnings ratio of 24.91 times trailing twelve-month earnings, positioned in the middle of the peer range. This compares favourably to Neuland Labs' elevated 93.42 times and Acutaas Chemical's 57.52 times, whilst commanding a premium to Natco Pharma's 9.42 times and Alembic Pharma's 22.67 times. The premium to Natco and Alembic appears justified given Granules India's superior growth momentum and margin expansion trajectory.
The price-to-book value ratio of 3.39 times represents a significant discount to specialty players like Acutaas Chemical (11.68 times) and Neuland Labs (10.33 times), reflecting the market's recognition of Granules India's more commoditised product portfolio. However, the company's improving margins and consistent execution suggest this valuation gap may narrow over time as the company demonstrates sustained profitability improvements.
Granules India's debt-to-equity ratio of 0.30 positions it conservatively within the peer group, providing financial flexibility for future growth initiatives. The dividend yield of 0.27% remains modest compared to Alembic Pharma's 1.44%, reflecting management's preference to reinvest earnings in capacity expansion rather than distribute cash to shareholders at this stage of the company's growth trajectory.
Valuation Analysis: Fair Value with Growth Potential
At the current market price of ₹556.40, Granules India trades at a trailing P/E ratio of 24.91 times, representing a 24.5% discount to the pharmaceutical sector average of 33 times. This valuation discount appears reasonable given the company's exposure to the generics segment, which typically commands lower multiples than specialty pharmaceutical manufacturers. However, the company's consistent margin expansion and strong operational execution suggest the discount may be excessive relative to its growth profile.
The price-to-book value ratio of 3.39 times compares favourably to the company's historical trading range, though it represents a premium to some peers like Natco Pharma (1.70 times) and Alembic Pharma (2.83 times). This premium reflects the market's recognition of Granules India's improving return ratios and balance sheet strength. The company's book value per share stands at ₹153.19, implying the stock trades at 2.21 times this intrinsic measure.
Enterprise value metrics provide additional perspective on valuation. The EV/EBITDA multiple of 13.53 times and EV/EBIT multiple of 18.19 times suggest moderate valuation levels relative to the company's earnings power. The EV/Sales ratio of 2.88 times reflects the market's assessment of the company's profitability profile and growth prospects. The PEG ratio of 1.91 indicates the stock is trading at nearly twice its five-year earnings growth rate of 5.92%, suggesting limited valuation upside at current levels unless growth accelerates.
The stock currently trades 11.32% below its 52-week high of ₹627.45, presenting a potential entry opportunity for investors with a medium-term investment horizon. The 52-week low of ₹412.05 provides a reference point for downside risk, with the current price representing a 35.03% premium to this level. The recent valuation grade change to "Expensive" from "Fair" in October 2025 suggests the market has re-rated the stock based on improved operational performance, though this also implies limited near-term upside from valuation expansion.
Shareholding Pattern: Institutional Confidence Remains Stable
The shareholding pattern of Granules India reflects a stable ownership structure with promoters maintaining a consistent stake and institutional investors demonstrating measured confidence. Promoter holding stood at 38.82% as of December 2025, unchanged from the previous quarter and down marginally from 38.85% in December 2024. This stable promoter stake, with zero pledging of shares, signals strong management confidence and alignment with minority shareholders.
| Category | Dec'25 | Sep'25 | Jun'25 | Mar'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter | 38.82% | 38.82% | 38.82% | 38.84% | 0.00% |
| FII | 13.55% | 14.09% | 13.24% | 15.15% | -0.54% |
| Mutual Funds | 5.35% | 6.54% | 12.24% | 11.57% | -1.19% |
| Insurance | 10.73% | 10.59% | 10.50% | 10.13% | +0.14% |
| Other DII | 1.40% | 0.79% | 0.79% | 0.75% | +0.61% |
| Non-Institutional | 30.15% | 29.17% | 24.41% | 23.57% | +0.98% |
Foreign institutional investor (FII) holding declined marginally to 13.55% in Q3 FY26 from 14.09% in the previous quarter, continuing a gradual reduction trend from the 15.87% stake held in December 2024. This 1.60 percentage point decline over the past year suggests some profit-booking by foreign investors following the stock's strong performance, though the absolute level of FII participation remains healthy at over 13%.
Mutual fund holdings witnessed a more pronounced decline, falling to 5.35% in December 2025 from 6.54% in the previous quarter and 10.39% a year ago. This 5.04 percentage point reduction over the past year represents the most significant shift in the shareholding pattern and may reflect portfolio rebalancing by domestic fund managers or concerns about near-term growth sustainability. The presence of 18 mutual fund schemes suggests diversified domestic institutional interest despite the recent reduction.
Insurance company holdings showed a contrasting trend, increasing steadily to 10.73% in Q3 FY26 from 8.44% in December 2024. This 2.29 percentage point accumulation over the past year indicates growing confidence from long-term institutional investors who typically focus on quality businesses with sustainable competitive advantages. The sequential increase of 14 basis points from September 2025 suggests continued accumulation.
Non-institutional holdings (largely comprising retail and high-net-worth individuals) increased to 30.15% in December 2025 from 25.71% a year ago, reflecting growing retail interest in the stock. The 98 basis point sequential increase from September 2025 indicates sustained buying by smaller investors, potentially attracted by the company's consistent operational performance and growth trajectory.
Stock Performance: Medium-Term Outperformance Despite Near-Term Volatility
Granules India's stock price performance presents a nuanced picture of medium-term outperformance tempered by recent consolidation. The stock has delivered a three-year return of 94.75%, significantly outpacing the Sensex's 36.73% return over the same period, generating alpha of 58.02 percentage points. This substantial outperformance reflects the market's recognition of the company's operational improvements and strategic positioning over the medium term.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -1.40% | -1.14% | -0.26% |
| 1 Month | -5.88% | -1.20% | -4.68% |
| 3 Months | +0.10% | -2.19% | +2.29% |
| 6 Months | +20.88% | +2.59% | +18.29% |
| YTD | -7.04% | -3.04% | -4.00% |
| 1 Year | +2.85% | +8.52% | -5.67% |
| 2 Years | +29.62% | +15.47% | +14.15% |
| 3 Years | +94.75% | +36.73% | +58.02% |
| 5 Years | +65.62% | +60.30% | +5.32% |
However, near-term performance has been more challenging. The stock has declined 5.88% over the past month, underperforming the Sensex by 4.68 percentage points, and is down 7.04% year-to-date versus the Sensex's 3.04% decline. This recent underperformance coincides with the stock's valuation grade change to "Expensive" in October 2025, suggesting investors are taking profits after the strong run-up earlier in the year.
The six-month return of 20.88% significantly outpaces the Sensex's 2.59% return, generating alpha of 18.29 percentage points. This performance reflects the market's positive response to the company's consistent quarterly results and margin expansion during the second half of 2025. The stock's technical trend changed to "Mildly Bullish" on January 22, 2026, at ₹570.55, following a brief period of bearish sentiment.
The stock exhibits high volatility with a beta of 1.32, indicating it moves 32% more than the broader market. This high-beta characteristic, combined with annualised volatility of 32.50%, classifies Granules India as a "HIGH RISK LOW RETURN" stock over the past year based on risk-adjusted metrics. The Sharpe ratio remains positive but modest, reflecting the stock's volatility relative to its absolute returns.
From a technical perspective, the stock trades below all key moving averages—5-day (₹573.11), 20-day (₹568.71), 50-day (₹581.24), 100-day (₹567.17), and 200-day (₹529.38)—suggesting near-term technical weakness. However, the MACD indicator shows "Mildly Bearish" on the weekly chart but "Bullish" on the monthly chart, indicating potential divergence between short-term and medium-term trends. On-balance volume (OBV) trends "Mildly Bullish" on the weekly timeframe, suggesting accumulation despite price weakness.
Investment Thesis: Quality Business at Fair Valuation
Granules India presents a compelling investment case built on four key pillars: improving financial trends, good quality fundamentals, reasonable valuation, and constructive technical setup. The company's overall Mojo score of 68 out of 100 places it in the "HOLD" category, reflecting a balanced assessment of opportunities and risks.
The company's quality credentials remain robust, with a quality grade of "GOOD" based on long-term financial performance. Key quality indicators include a healthy five-year sales growth rate of 10.88%, strong EBIT to interest coverage of 12.20 times, and conservative leverage with a debt-to-EBITDA ratio of 1.41 times. The absence of promoter pledging and institutional holdings of 31.03% further validate the company's quality credentials.
The financial trend assessment of "POSITIVE" reflects the company's record quarterly performance across multiple metrics. Net sales, operating profit, and PAT all reached historical highs in Q3 FY26, whilst cash and cash equivalents for the half-year period stood at the highest levels. The operating profit to interest coverage ratio of 10.74 times in the quarter demonstrates strong debt servicing capacity.
However, the valuation grade of "EXPENSIVE" tempers the investment case. The stock's transition through multiple valuation grades in 2025—from "Very Attractive" in August to "Expensive" by October—reflects the market's rapid re-rating of the stock. At current levels, the stock offers limited upside from multiple expansion, with the PEG ratio of 1.91 suggesting the stock is trading at nearly twice its historical growth rate.
Key Strengths & Risk Factors
✓ KEY STRENGTHS
- Record Financial Performance: Q3 FY26 delivered highest-ever quarterly sales (₹1,387.94 crores) and net profit (₹150.21 crores)
- Margin Expansion: Operating margin improved 204 bps YoY to 22.36%, reflecting better product mix and operational efficiency
- Strong Return Ratios: ROE of 15.81% and ROCE of 18.24% demonstrate efficient capital deployment
- Conservative Balance Sheet: Net debt-to-equity of 0.30 and debt-to-EBITDA of 1.41 provide financial flexibility
- Robust Cash Generation: Operating cash flow doubled to ₹866 crores in FY25, with cash reserves of ₹619 crores in H1 FY26
- Vertically Integrated Model: Control over API production provides cost advantages and supply security
- Zero Promoter Pledging: Stable 38.82% promoter stake with no pledging signals strong management confidence
⚠ KEY CONCERNS
- Modest Long-Term Growth: Five-year EBIT CAGR of 5.92% raises questions about sustained earnings expansion
- Rising Interest Costs: Interest expenses grew 21.19% in H1 FY26, warranting monitoring amid capacity expansion
- Expensive Valuation: PEG ratio of 1.91 and "Expensive" valuation grade limit upside from multiple expansion
- High Volatility: Beta of 1.32 and 32.50% annualised volatility classify stock as high-risk
- Mutual Fund Exodus: MF holdings declined from 10.39% to 5.35% over past year, signalling institutional caution
- Near-Term Underperformance: Stock down 5.88% over past month and 7.04% YTD, underperforming Sensex
- Technical Weakness: Trading below all key moving averages suggests near-term price pressure
Outlook: What to Watch
POSITIVE CATALYSTS
- Sustained Margin Expansion: Continued improvement beyond 22% operating margins would validate pricing power
- Revenue Growth Acceleration: Maintaining 20%+ YoY growth would support current valuation levels
- Market Share Gains: Evidence of gaining share in key API/formulation markets
- Capacity Utilisation: Improved utilisation of recent capex investments driving operating leverage
- Institutional Re-Entry: Renewed buying by mutual funds and FIIs following recent profit-booking
RED FLAGS
- Margin Compression: Any reversal in operating margin expansion would challenge investment thesis
- Revenue Growth Slowdown: Sequential or YoY decline in sales would raise concerns
- Rising Debt Levels: Significant increase in leverage beyond current conservative levels
- Working Capital Deterioration: Decline in debtor turnover or cash conversion efficiency
- Continued Institutional Selling: Further reduction in FII/MF holdings below current levels
The Verdict: Quality Business, But Wait for Better Entry
Score: 68/100
For Fresh Investors: Not recommended for fresh purchases at current levels. Granules India is a quality pharmaceutical manufacturer with improving operational metrics, but the "Expensive" valuation grade and recent price weakness suggest waiting for a better entry point. Consider accumulating on dips towards ₹500-520 levels, which would offer a more favourable risk-reward profile.
For Existing Holders: Continue to hold your positions. The company's record quarterly performance, consistent margin expansion, and strong balance sheet justify maintaining exposure. The medium-term growth trajectory remains intact despite near-term volatility. Use any significant weakness as an opportunity to average up, but avoid aggressive accumulation at current valuations.
Fair Value Estimate: ₹580-600 (4.2%-7.8% upside from current levels of ₹556.40)
Granules India's vertically integrated business model and operational excellence provide a solid foundation for long-term wealth creation, but current valuations—trading at nearly twice its historical growth rate—leave limited margin of safety. The stock warrants a "HOLD" rating as existing shareholders benefit from the company's improving fundamentals, whilst fresh investors should await a more attractive entry point that better balances quality with valuation.
Note: ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results, and all investments carry inherent risks including the potential loss of principal.
